Mar 13, 2019 / 12:00PM GMT
Gena Wang - Barclays Bank PLC, Research Division - Research Analyst
Good morning, everyone. My name is Gena Wang, I'm [a biotech] analyst from Barclays.
It is my great pleasure to introduce our first speaker, Tom Kassberg, Chief Business Officer of Ultragenyx.
Thomas R. Kassberg - Ultragenyx Pharmaceutical Inc. - Chief Business Officer & Executive VP
Thanks, Gena. Let me see -- figure out the slides. So I'm Tom Kassberg, Chief Business Officer of Ultragenyx, and I'm pleased to be here to talk to you about Ultragenyx today.
So standard legal warning for the presentation to follow. So Ultragenyx, for some of you, I'll give you a quick introduction, was founded in 2010, went IPO in 2014. And it's an -- we talk about as a company that was built rare by design. So from the beginning, developed as a specialist rare disease company. We have -- in terms of -- we forged many new approaches and with multiple modalities that we currently employ to address these rare diseases. About 1.5 years ago, we added a gene therapy platform, which is now an
Ultragenyx Pharmaceutical Inc at Barclays Global Healthcare Conference Transcript
Mar 13, 2019
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers